The FDA placed a clinical hold on the Phase 2 study of Rocket Pharmaceuticals Inc. on August 11, 2025.
2 reports, 2 independent
Updated Aug 4
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA placed a clinical hold on the Phase 2 study of Rocket Pharmaceuticals Inc. on August 11, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA approved the relaunch of Rocket's clinical trial following a previous clinical hold.1 source
FDA placed clinical hold on Rocket Pharma's Phase 2 study.1 source
Keep exploring
The entities involved
Related events
- FDA placed a clinical hold on the drug application submitted by Bright Minds Biosciences Inc.
- Cloudbreak Pharma Inc. intends to meet with the FDA to review its study findings.
- The FDA is a U.S. government agency, a basic descriptive fact about the regulator.
- ADC Therapeutics received accelerated approval for its drug from the FDA.
- FDA failed to update warning labels despite confirmed risks associated with a product.
Coverage
Newest first; wire copies grouped- yahoo.com
- prnewswire_rocketClass Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT) - August 11, 2025 Deadline to Join - Contact The Gross Law Firm